Cytodyne v. EAS
This article was originally published in The Tan Sheet
Executive Summary
EAS held in contempt by Newark, N.J. federal Judge Dickinson Debevoise Dec. 23 for violating preliminary injunction barring it from disseminating allegedly false, misleading ads for BetaLean HP. Contempt finding resulted from EAS' failure to stop making certain claims, including statements that BetaLean HP's proprietary formula enhances the thermogenic effect of the product's original ephedrine/caffeine combination. EAS has since removed the disputed claims from its Web site and, pursuant to the court's order, posted the following statement, which also must be distributed to firm's distributors, retailers: "A U.S. District Court found that this claim is not true and that the proprietary formula has been found to reduce and inhibit the overall thermogenic effect of the ephedrine and caffeine combination." Argument on Cytodyne's motion to dismiss an EAS countersuit will be Jan. 27 (1"The Tan Sheet" Dec. 9, 2002, p. 8)...
You may also be interested in...
Cytodyne “Before-After” Weight-Loss Photos Subject Of EAS Countersuit
"Before-and-after" photos used in ads for Cytodyne Technologies' Xenadrine weight-loss products are false and misleading, a countersuit filed by Golden, Colo.-based Experimental & Applied Sciences alleges
Cosmetics Europe Talks Microplastic: ECHA Frustrations, ‘Value Judgments’ And International Trade Uncertainty
The European Chemicals Agency's microplastic restriction proposal received committee backing in 2020 without changes sought by the cosmetics industry, which faces €15bn in projected costs and scarce alternatives at present. It may come down to EU Member States to decide whether the ECHA restriction proposal is proportionate in balancing environmental goals and socio-economic impacts.
Roche/Genentech Keeps Commitment To External Cancer Innovation
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: